Background
Pneumocystis pneumonia (PCP) is a growing concern as the immunocompromised population expands. Current laboratory approaches are limited. This systematic review aimed to evaluate metagenomic next-generation sequencing (MNGS) tests’ performance in detecting PCP.
Methods
Five databases were searched through December 19, 2022, to identify original studies comparing MNGS to clinically diagnosed PCP. To assess the accuracy, symmetric hierarchical summary receiver operating characteristic models were used.
Results
Eleven observational studies reporting 1132 patients (406 with PCP) were included. Six studies focused exclusively on recipients of biologic immunosuppression (none with HIV-associated immunosuppression). Six were exclusively on bronchoalveolar lavage, while one was on blood samples.
The sensitivity of MGNS was 0.96 (95% C.I.=0.90, 0.99) and specificity was 0.96 (95% C.I.=0.92, 0.98), with a negative and positive likelihood ratio of 0.02 (95%C.I.=0.01, 0.05) and 19.31 (95% C.I.=10.26, 36.36), respectively. A subgroup analysis of studies exclusively including bronchoalveolar lavage (BAL) and blood samples demonstrated a sensitivity of 0.94 (95% C.I.=0.78, 0.99) and 0.93 (95% C.I.=0.80, 0.98) and a specificity of 0.96 (95% C.I.=0.88, 0.99) and 0.98 (95% C.I.=0.76, 1.00), respectively. The sensitivity analysis on recipients of biologic immunosuppression showed a sensitivity and specificity of 0.96 (95%C.I.=0.90, 0.98) and 0.94 (95% C.I.=0.84, 0.98), respectively). The overall confidence in the estimates was low.
Conclusion
Despite the low certainty of evidence, MNGS detects PCP with high sensitivity and specificity. This also applies to recipients of biologic immunosuppression and tests performed exclusively on blood samples without the need for BAL. Further studies are required in individuals with HIV-associated immunosuppression.